Search the site

Research

KMT2A-rearranged acute lymphoblastic leukaemia

KMT2A-rearranged acute lymphoblastic leukaemia (ALL) represents a high risk subtype of childhood ALL. Historical treatment strategies have comprised of intensification with conventional chemotherapy. However, outcomes have remained consistently poor compared to the advances that have been seen for other ALL subtypes, particularly for infants diagnosed before their first birthday

New treatments on horizon for rarest child brain cancers

The WA Kids Cancer Centre has a suite of world-leading research projects to unlock new treatments for childhood cancers.

Research

Combining CRISPR-Cas9 and TCR exchange to generate a safe and efficient cord blood-derived T cell product for pediatric relapsed AML

Hematopoietic cell transplantation (HCT) is an effective treatment for pediatric patients with high-risk, refractory, or relapsed acute myeloid leukemia (AML). However, a large proportion of transplanted patients eventually die due to relapse. To improve overall survival, we propose a combined strategy based on cord blood (CB)-HCT with the application of AML-specific T cell receptor (TCR)-engineered T cell therapy derived from the same CB graft.

Research

Exploring Exclusive Breastfeeding and Childhood Cancer Using Linked Data

Citation: Bailey HD. Exploring Exclusive Breastfeeding and Childhood Cancer Using Linked Data. JAMA Netw Open. 2024;7(3):e243075 Keywords:

News & Events

New study exposes link between pesticides and childhood brain tumours

A new Telethon Institute study has revealed a potential link between pesticide treatments in the home and a higher risk of children developing brain tumours.

News & Events

Exposure to diesel exhaust increases risk of child brain tumours

Research at Telethon Institute has shown a correlation between brain tumours in young children and their parents' exposure to diesel exhaust fumes before birth.

News & Events

Researchers find new insight into genetics of aggressive cancer

Researchers at Telethon Institute have found genetic differences in the rare and aggressive NUT-midline carcinoma, presenting new treatment opportunities.